
    
      -  Participants will receive study treatment as an outpatient. Study treatment will be
           given in 3-week cycles.

        -  Sunitinib will be taken orally once per day for the first two weeks (days 1-14) of each
           treatment cycle.

        -  Gemcitabine will be given intravenously at the study clinic on days 1 and 8 of each
           treatment cycle.

        -  Before receiving sunitinib and gemcitabine on day 1 of each cycle the following will be
           performed: physical exam, performance status assessment and blood work. Before receiving
           gemcitabine on day 8 the following will be performed: physical exam, performance status
           assessment and blood work. Every 3 cycles a CT scan will be performed to measure the
           tumor.
    
  